Many findings have shown that pyruvate kinase type M2 (PKM2) plays crucial roles in regulating the occurrence and development of various human cancers; however, its roles in ovarian cancer oncogenesis remain to be determined.
Background
Ovarian cancer is one of the most common gynecologic cancers, and its incidence is third highest among the gynecologic malignant tumors. Patient survival is usually poor, and the 5-year survival rate is still poorer [1] . To date, the molecular mechanisms involved in ovarian cancer incidence and development remain largely unknown. While numerous studies have shown that aberrant oncogene expression and their products or key signal molecules, including protein kinases, may play essential roles in cancer development [2] , the exact pathways involved in ovarian cancer remain to be determined. Investigation of the molecular mechanisms of ovarian cancer occurrence, development, invasion, metastasis, and survival will be of great value for providing a foundation for clinical treatment and for studying the prognosis of patients with ovarian cancer. In recent years, an increasing number of findings have shown that abnormal expression of pyruvate kinase type M2 (PKM2) is closely associated with tumor progression [3] [4] [5] [6] [7] , but whether PKM2 is related to ovarian cancer remains unclearly. Therefore, in this study, we investigated the expression of PKM2 in ovarian cancer tissues, and the effect of PKM2 on ovarian cancer cell proliferation, growth, and survival, as well as the potential mechanism related with PKM2 on ovarian cancer development, by overexpressing and underexpressing PKM2. Our results may form the basis for further understanding the molecular mechanisms of ovarian cancer incidence and development.
Material and Methods

Tissue samples
We obtained 114 paraffin-embedded serous ovarian cancer tissue samples and 50 paraffin-embedded non-cancerous ovarian tissue samples from patients who underwent surgical resection between January 2003 and December 2010 at Fuzhou General Hospital and the Cancer Hospital of Fujian Province (Fujian, China). All samples had been diagnosed pathologically and classified by doctors at the Departments of Pathology of both hospitals.
Ethics statement
The Ethics Committees of Fuzhou General Hospital and the Cancer Hospital of Fujian Province approved this study. In addition, all patients consented to the use of their tissue samples for research.
Immunohistochemistry (IHC) for PKM2
Anti-PKM2 antibody was purchased from Abcam (Cambridge, MA, USA). The other IHC reagents were EliVision plus immunohistochemical staining reagent, citric acid antigen repair solution, concentrated diaminobenzidine (DAB) color reagent kit, and hematoxylin restaining reagent, which were all purchased from Maixin (Fujian, China). IHC detection of PKM2 expression in the cancer and non-cancerous tissues was performed based on the method by Liu et al. for human EGFR 2 (HER2) in gastric cancer [8] . All results were evaluated by pathologists using a semi-quantitative method. Based on the degree of tissue section staining, the results were divided into 4 grades: -, no staining; +, weak staining; ++, moderate staining; and +++, strong staining. Staining intensity ³ + was considered positive. PKM2 expression was determined by ratios, where PKM2 expression levels in the cancer tissue were divided by that in non-cancerous tissues. A ratio >1 indicated PKM2 overexpression in the cancer tissues; a ratio =1 indicated no significant difference between PKM2 expression levels in the cancer and non-cancerous tissues; and a ratio <1 indicated downregulated PKM2 in the cancer tissues.
PLVX-Neo-IRES-ZsGreen1-PKM2 expression vector construct
The pLVX-Neo-IRES-ZsGreen1 lentivirus vector was purchased from Genomeditech (Shanghai, China), and the pDsRed-Express-C1-PKM2 plasmid (a gift from Professor RN Bamezai) was used as the template. To clone human PKM2 cDNA into the pLVX-Neo-IRES-ZsGreen1 vector, XhoI and NotI restriction sites were inserted into the PCR products using the following primers: 5'-CCGCTCGAGATGTCGAAGCCCCATAGTGAAG-3' (forward) and 5'-ATAAGAATGCGGCCGCTCACGGCACAGGAACAACACGC-3' (reverse). After confirming the PKM2 sequences by sequencing, the plasmid was cotransfected into 293T cells with the lentivirus packaging plasmids pMD2.G and psPAX2 to produce lentivirus particles. The PKM2 lentivirus particles were then used to transduce SKOV3 and HEY ovarian cells. SKOV3 and HEY cells stably overexpressing PKM2 or empty vector were established by first transducing the cells with PKM2 lentivirus particles or empty vector lentivirus particles, and then screening them using G418.
Silencing PKM2 expression in SKOV3 and HEY cells with PKM2 siRNA SKOV3 and HEY cells which exhibited low-expressed PKM2 were obtained through silencing PKM2 by transfected with PKM2 siRNA (targeting on the sites of 1280-1298 bp of PKM2) (sense: CCAUAAUCGUCCUCACCAATT, antisense: UUGGUGAGGACGAUUAUGGTT, purchased from RUIBIO Co., Guangzhou, China). At the same time, scramble siRNA (negative siRNA) (Sense: AAACCUUUCCCCCUAAACGTT, antisense: CGUUUAGGGGGAAAGGUUUTT), which was also obtained from the same company, was transfected into SKOV3 and HEY cells, respectively, to serve as negative controls.
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Western blot detection of PKM2, CCND1, and CDKN1A expression in SKOV3 and HEY cells PKM2, CCND1, and CDKN1A expression in SKOV3 and HEY cells were detected by Western blotting, which was based on our previously described methods [9] , but the ECL substrate used was Pierce™ ECL Western Blotting Substrate and the results were detected by using ChemiDoc™ Touch Imaging System (Bio-Rad Company, USA). The anti-PKM2 antibody (1: 1000) used for the Western blotting was the same as that used for IHC. The anti-CCND1 (1: 1000) and anti-CDKN1A (1: 1000) used for the Western blotting were purchased from ZSGB-BIO (Beijing, China) and Santa Cruz (CA, USA), respectively. b-Actin antibody (1: 4000) serving as the control was purchased from abMart (Shanghai, China).
CCK-8 assay detection of SKOV3 and HEY cell proliferation SKOV3 and HEY cells were divided into 5 groups: untransfected cells, transduced with empty vector lentivirus particles, transduced with PKM2 lentivirus particles, transfected with scramble siRNA (negative siRNA), and transfected with PKM2 siRNA. The cells were seeded in 96 well-plates (cells, 4000 cells/well; culture medium, 100 µL/well). Seeding per group was repeated in 6 different wells. After overnight culture in a 37°C incubator with 5% CO 2 , the cells were grown in culture medium containing 2% fetal bovine serum (FBS) for a total 72 h; during this period, CCK-8 assays were performed at 6, 24, 48, and 72 h, respectively, which were achieved by adding CCK-8 (10 μL, 5 mg/mL) (Genview, Beijing, China) to each well, and cells were cultured for another 1 h. The blank contained culture medium and CCK-8. The absorbance at 450 nm (A450) against that of the blank was measured using a microplate reader (Bio-Tek, VT, USA).
Colony forming assay to detect SKOV3 and HEY cell growth
A density with 500 SKOV3 and HEY cells/per well of a 6-well plate was applied to grow SKOV3 and HEY cells, respectively, to perform colony forming assays. After cells had grown for 14 days, the formed cell clones were checked. The clones were then fixed by menthol and stained with 0.1% crystal violet at room temperature. Clones containing 50 or more than 50 cells were regarded as a positive clone when observed under a microscope, and the colony forming rate=numbers of positive clones/total cell seeded in the well×100%.
Annexin V-FITC+Propidium Iodide staining combined flow cytometry assay to detect SKOV3 and HEY cell apoptosis Annexin V-FITC+Propidium Iodide (PI) kits for detection of cell apoptosis were purchased from KeyGen Biotech Company (Nanjing, Jiangsu, China). Cell apoptosis in SKOV3 and HEY cells were examined with flow cytometry by staining with the kit according to the manufacturer's instructions.
PI staining combined flow cytometry assay to detect SKOV3 and HEY cell cycle Propidium Iodide (PI) staining kits for cell cycle were purchased from Beyotime Institute of Biotechnology (Haimen, Jiangsu, China). Cell cycle was analyzed by flow cytometry after SKOV3 and HEY cells had been stained with the kit according to the manufacturer's instruction.
Statistical analysis
Statistical differences in PKM2 expression levels between the serous ovarian cancer tissues and non-cancerous tissues were determined by the Wilcoxon signed ranks test. The chi-square test and Fisher's exact test were used when necessary to analyze the clinical significance of differences between PKM2 expression levels and patient clinicopathological features. The single-factor analysis of variance (ANOVA) and independent t test were used to analyze differences in the proliferation, colony forming, apoptosis, and different stages of cell cycle in the different groups of SKOV3 and HEY cells. All analyses were performed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA). p<0.05 was considered statistically significant.
Results
PKM2 was overexpressed in serous ovarian cancer tissues
The IHC results showed that among the 114 serous ovarian cancer tissues, 100 (87.7%) had positive PKM2 expression. By contrast, only 4 of the 50 non-cancerous ovarian tissues had positive PKM2 expression. The PKM2 expression levels between the cancer and non-cancerous tissues were statistically significantly different (P<0.001) (Figure 1 ). Subsequently, PKM2 expression in the cancer tissues was divided into low expression (PKM2 expression of -or +) and high expression (PKM2 expression of ++ or +++) groups. The results showed that PKM2 expression was not related with patient age, sex, tumor-nodemetastasis (TNM) stage, or metastasis (all, p>0.05), but was related with tumor size (³7.5 cm vs. <7.5 cm, P=0.046), where more patients with high PKM2 expression had tumors ³7.5 cm (25/61, 40.98% vs. 11/48, 22.92%, P=0.046) among 109 cases of patients who had the available data of tumor size. These results suggest that PKM2 overexpression may be related to ovarian cancer development and growth.
PKM2 overexpression increased SKOV3 and HEY cell proliferation
The CCK-8 assay showed that PKM2 overexpression significantly increased SKOV3 cell and HEY cell proliferation, with the highest increased peak at 72 h at the determined time periods in this study, compared to those of empty vector transduction or wild-type cells (p<0.05) after cells had grown for 48 h, whereas no statistically significant difference was detected between empty vector transduction cells and wild-type cells in terms of cell proliferation (Figure 2A, 2B) . Silenced PKM2 expression by siRNA significantly inhibited SKOV3 and HEY cell proliferation compared to those in both SKOV3 and HEY cells transfected with scramble siRNA (negative siRNA), both p<0.05, after cells had grown for 48 h (Figure 2A, 2B) . The results indicate that PKM2 overexpression can lead to increased ovarian cancer cell proliferation, whereas PKM2 downexpression can lead to decreased ovarian cancer cell proliferation.
PKM2 overexpression increased SKOV3 and HEY cell growth Colony forming assay showed that PKM2 overexpression significantly increased SKOV3 cell and HEY cell growth compared to those of empty vector transduction, both p<0.05 ( Figure 3A-3D ). Similar to results of cell proliferation assays, no statistically significant difference was detected between empty vector Figure 3A-3D ). Silenced PKM2 expression by siRNA significantly inhibited SKOV3 and HEY cell growth compared to those in both SKOV3 and HEY cells transfected with scramble siRNA (negative siRNA), both p<0.05 ( Figure 3A-3D) .
The results indicate that PKM2 overexpression can lead to increased ovarian cancer cell growth, whereas PKM2 downexpression can lead to decreased ovarian cancer cell growth.
PKM2 overexpression decreased SKOV3 and HEY cell apoptosis
Annexin V-FITC+Propidium Iodide staining combined flow cytometry assay showed that PKM2 overexpression decreased SKOV3 cell and HEY cell apoptosis compared to those in empty vector transduction and wild-type cells, both p<0.05 ( Figure 4A-4D) , whereas no statistical significant difference was detected between empty vector transduction cells and wild-type cells in cell apoptosis (Figure 4A-4D ). Silenced PKM2 expression by siR-NA significantly increased SKOV3 and HEY cell apoptosis compared to those in both SKOV3 and HEY cells transfected with scramble siRNA (negative siRNA), both p<0.05 ( Figure 4A-4D) .
The results indicate that PKM2 overexpression can lead to decreased ovarian cancer cell apoptosis, whereas PKM2 downexpression can lead to increased ovarian cancer cell apoptosis.
PKM2 overexpression increased ovarian cancer cell proliferation, growth, and survival via increased S stage of cell cycle progression Propidium iodide staining combined flow cytometry assay cell cycle showed PKM2 overexpression significantly increased S stage of cell cycle progression in SKOV3 cells and HEY cells, compared to those in empty vector transduction and wildtype, both p<0.05 ( Figure 5A-5D ), whereas no statistically significant difference was detected between empty vector transduction cells and wild-type cells in S stage of cell cycle progression ( Figure 5A-5D ). Silenced PKM2 expression by siRNA significantly decreased S stage of cell cycle progression in SKOV3 and HEY compared to those in SKOV3 and HEY cells transfected with scramble siRNA (negative siRNA), both p<0.05 ( Figure 5A-5D ). Additionally, overexpression of PKM2 also decreased G1 stage, and low expression of PKM2 also increased G1 stage of cell cycle progression of SKOV3 and HEY cells ( Figure 5A-5D ). The results indicate that PKM2 overexpression can lead to increased ovarian cancer cell development through regulating cell cycle progression.
PKM2 overexpression increased CCND1 and decreased CDKN1A expression in SKOV3 and HEY cells
The roles of CCND1 and CDKN1A in mediating cell cycle progression have been widely documented [10, 11] . Many studies have confirmed that CCND1 mainly has an oncogenic effect, whereas CDKN1A mainly acts as a suppressor of cancer, and both of them are closely linked to development of various human cancers [12, 13] . However, the role of PKM2 in promoting ovarian cancer cell cycle progression remains to be determined. As shown in Figure 6A and 6B, Western blotting results showed that CCND1 was upregulated and downregulated in PKM2 overexpressed and underexpressed SKOV3 and HEY cells, respectively; but CDKN1A was downregulated and upregulated in PKM2 overexpressed and underexpressed SKOV3 and HEY cells, respectively. The results indicate that PKM2 overexpression led to increase ovarian cancer cell development via regulating cell cycle progression, and may be associated with its regulation of CCND1 and CDKN1A expression. 
Discussion
PKM2 is a well-known key enzyme of aerobic glycolysis, with high affinity binding with its substrate phosphoenolpyruvic acid (PEP). PKM2 has strong catalytic ability and can catalyze PEP conversion to pyruvate, which is a rate-limiting step of glycolysis, through which it provides energy for cell growth and proliferation. Mammalian cells have 4 pyruvate kinase isozymes -PKM1, PKM2, PKL, and PKR -which are distributed in different tissues and cells. However, in tumor formation, PKM2 gradually replaces the other isozymes to become the major isozyme, and is highly expressed in malignant cells and tissues [10] . PKM2 expression is often accompanied by high levels of nucleic acid synthesis, which is frequently observed in almost all proliferating cells (e.g., embryonic cells, adult stem cells, and cancer cells) [14] .
Early studies have also consistently demonstrated that PKM2 (the dimeric form of PKM2, also termed TuM2-PK) is a tumor marker whose levels in serum have great value in colon cancer, renal cell carcinoma, and lung cancer diagnosis, therapeutic effect evaluation, treatment monitoring, and prognosis evaluation [15] [16] [17] . Recent data from large studies have demonstrated that PKM2 expression is abnormal in many cancer cells and tissues and is closely related to the malignant biological behavior of these cells, and it plays an important role in regulating cancer metabolism and promoting cancer cell growth, proliferation, invasion, and metastasis via various molecular mechanisms [14, 18, 19] . Zhou et al. showed that PKM2 is overexpressed in colon cancer and is related to both cancer stage and lymph metastasis. Inhibiting PKM2 expression suppressed colon cancer cell proliferation and migration [20] . Kwon et al. indicated that PKM2 is not only overexpressed in gastric cancer tissues, but is also related with shorter survival in gastric cancer patients, which may be related to the capability of PKM2 to increase cell survival by mediating Bcl-xL transcription levels [21] . Liang et al. demonstrated that Cdc25A, a dual-specificity phosphatase, regulates PKM2 dephosphorylation, which in turn increases the Warburg effect, and brain carcinogenesis [22] . Data from the study by Park et al. demonstrated that PKM2 regulation of glycolysis is related to sirtuin type 2 (SIRT2)-associated deacetylation and tetramerization [23] . Park et al. found that the direct interaction of AKT and PKM2 results in Ser202 phosphorylation in PKM2, which then causes PKM2 translocation into the nucleus, where it binds signal transducers and activators of transcription 5A (STAT5A), activating it and leading to increased expression of the oncogene cyclin D1 in response to insulin-like growth factor 1 (IGF1) treatment [24] . 
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Regarding the relationship between EGFR and PKM2, not only can EGFR activation increase tumor growth, PKM2 can also elevate EGF/EGFR activity [4] . Yang's group showed that EGFR activation could cause PKM2 translocation into the nucleus, where phosphorylation activates PKM2, which then interacts with b-catenin, leading to cyclin D1 expression, which is related with cancer cell proliferation [7] . These findings all demonstrate the important effects of PKM2 on human cancers.
However, the role of PKM2 in ovarian cancer is still poorly understood. To date, few investigations have focused on the relationship between PKM2 and ovarian cancer. Accordingly, we investigated its role in ovarian cancer in this study. We found that PKM2 was overexpressed in ovarian cancer tissues and that its upregulation was related to tumor size. Further research showed that PKM2 overexpression resulted in both elevated ovarian cancer cell proliferation, growth, and survival, which were related to overexpression contributing to increased cell cycle progression. Further data showed that the molecular mechanism of the function of PKM2 may be linked to its ability to change the expression levels of CCND1 and CDKN1A, which are 2 of the most widely demonstrated cell cycle regulators.
Conclusions
PKM2 is overexpressed in ovarian cancer tissue, and higher expression of PKM2 is related to larger tumor size as well as to increased ovarian cancer cell oncogenesis and development. Therefore, PKM2 may be a new treatment target in ovarian cancer.
